Soluble ST2 and galectin-3 in pediatric patients without heart failure

Jeffrey W. Meeusen, Jonathan N. Johnson, Amber Gray, Patricia Wendt, John L. Jefferies, Allan S Jaffe, Leslie J. Donato, Amy K. Saenger

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: Soluble ST2 (ST2) and galectin-3 (Gal3) are biomarkers of myocardial fibrosis and remodeling. This study provides a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure. Design and methods: Sera from 240 children, 40 males and 40 females from each of three age groups, (2-6 years, 7-11 years, and 12-17 years) without heart failure were identified from residual clinical testing. Serum ST2 and Gal3 were measured by ELISA. Results: Serum ST2 increased with age among males, but not females. However, the difference was not statistically significant at the 95th or 97.5th percentiles. No relationship was found between serum Gal3 concentrations and age or gender. Central 95th percentiles (2.5th to 97.5th) were 9-50 ng/mL for ST2 and 7-33 ng/mL for Gal3. Conclusions: We have presented baseline, normative data for ST2 and Gal3 in children. This will allow for study of the utility of these biomarkers in children with heart disease.

Original languageEnglish (US)
Pages (from-to)1337-1340
Number of pages4
JournalClinical Biochemistry
Volume48
Issue number18
DOIs
StatePublished - Dec 1 2015

Fingerprint

Galectin 3
Pediatrics
Heart Failure
Biomarkers
Serum
Heart Diseases
Fibrosis
Age Groups
Enzyme-Linked Immunosorbent Assay
Testing

Keywords

  • Biomarkers
  • Cardiomyopathy
  • Natriuretic peptides
  • Reference range

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Meeusen, J. W., Johnson, J. N., Gray, A., Wendt, P., Jefferies, J. L., Jaffe, A. S., ... Saenger, A. K. (2015). Soluble ST2 and galectin-3 in pediatric patients without heart failure. Clinical Biochemistry, 48(18), 1337-1340. https://doi.org/10.1016/j.clinbiochem.2015.08.007

Soluble ST2 and galectin-3 in pediatric patients without heart failure. / Meeusen, Jeffrey W.; Johnson, Jonathan N.; Gray, Amber; Wendt, Patricia; Jefferies, John L.; Jaffe, Allan S; Donato, Leslie J.; Saenger, Amy K.

In: Clinical Biochemistry, Vol. 48, No. 18, 01.12.2015, p. 1337-1340.

Research output: Contribution to journalArticle

Meeusen, JW, Johnson, JN, Gray, A, Wendt, P, Jefferies, JL, Jaffe, AS, Donato, LJ & Saenger, AK 2015, 'Soluble ST2 and galectin-3 in pediatric patients without heart failure', Clinical Biochemistry, vol. 48, no. 18, pp. 1337-1340. https://doi.org/10.1016/j.clinbiochem.2015.08.007
Meeusen, Jeffrey W. ; Johnson, Jonathan N. ; Gray, Amber ; Wendt, Patricia ; Jefferies, John L. ; Jaffe, Allan S ; Donato, Leslie J. ; Saenger, Amy K. / Soluble ST2 and galectin-3 in pediatric patients without heart failure. In: Clinical Biochemistry. 2015 ; Vol. 48, No. 18. pp. 1337-1340.
@article{3a6a0434d0dc47d88d1e560391b8ae5d,
title = "Soluble ST2 and galectin-3 in pediatric patients without heart failure",
abstract = "Objectives: Soluble ST2 (ST2) and galectin-3 (Gal3) are biomarkers of myocardial fibrosis and remodeling. This study provides a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure. Design and methods: Sera from 240 children, 40 males and 40 females from each of three age groups, (2-6 years, 7-11 years, and 12-17 years) without heart failure were identified from residual clinical testing. Serum ST2 and Gal3 were measured by ELISA. Results: Serum ST2 increased with age among males, but not females. However, the difference was not statistically significant at the 95th or 97.5th percentiles. No relationship was found between serum Gal3 concentrations and age or gender. Central 95th percentiles (2.5th to 97.5th) were 9-50 ng/mL for ST2 and 7-33 ng/mL for Gal3. Conclusions: We have presented baseline, normative data for ST2 and Gal3 in children. This will allow for study of the utility of these biomarkers in children with heart disease.",
keywords = "Biomarkers, Cardiomyopathy, Natriuretic peptides, Reference range",
author = "Meeusen, {Jeffrey W.} and Johnson, {Jonathan N.} and Amber Gray and Patricia Wendt and Jefferies, {John L.} and Jaffe, {Allan S} and Donato, {Leslie J.} and Saenger, {Amy K.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.clinbiochem.2015.08.007",
language = "English (US)",
volume = "48",
pages = "1337--1340",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "18",

}

TY - JOUR

T1 - Soluble ST2 and galectin-3 in pediatric patients without heart failure

AU - Meeusen, Jeffrey W.

AU - Johnson, Jonathan N.

AU - Gray, Amber

AU - Wendt, Patricia

AU - Jefferies, John L.

AU - Jaffe, Allan S

AU - Donato, Leslie J.

AU - Saenger, Amy K.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objectives: Soluble ST2 (ST2) and galectin-3 (Gal3) are biomarkers of myocardial fibrosis and remodeling. This study provides a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure. Design and methods: Sera from 240 children, 40 males and 40 females from each of three age groups, (2-6 years, 7-11 years, and 12-17 years) without heart failure were identified from residual clinical testing. Serum ST2 and Gal3 were measured by ELISA. Results: Serum ST2 increased with age among males, but not females. However, the difference was not statistically significant at the 95th or 97.5th percentiles. No relationship was found between serum Gal3 concentrations and age or gender. Central 95th percentiles (2.5th to 97.5th) were 9-50 ng/mL for ST2 and 7-33 ng/mL for Gal3. Conclusions: We have presented baseline, normative data for ST2 and Gal3 in children. This will allow for study of the utility of these biomarkers in children with heart disease.

AB - Objectives: Soluble ST2 (ST2) and galectin-3 (Gal3) are biomarkers of myocardial fibrosis and remodeling. This study provides a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure. Design and methods: Sera from 240 children, 40 males and 40 females from each of three age groups, (2-6 years, 7-11 years, and 12-17 years) without heart failure were identified from residual clinical testing. Serum ST2 and Gal3 were measured by ELISA. Results: Serum ST2 increased with age among males, but not females. However, the difference was not statistically significant at the 95th or 97.5th percentiles. No relationship was found between serum Gal3 concentrations and age or gender. Central 95th percentiles (2.5th to 97.5th) were 9-50 ng/mL for ST2 and 7-33 ng/mL for Gal3. Conclusions: We have presented baseline, normative data for ST2 and Gal3 in children. This will allow for study of the utility of these biomarkers in children with heart disease.

KW - Biomarkers

KW - Cardiomyopathy

KW - Natriuretic peptides

KW - Reference range

UR - http://www.scopus.com/inward/record.url?scp=84949093186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949093186&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2015.08.007

DO - 10.1016/j.clinbiochem.2015.08.007

M3 - Article

C2 - 26277636

AN - SCOPUS:84949093186

VL - 48

SP - 1337

EP - 1340

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 18

ER -